Aprepitant for Heart Failure
This trial is testing whether a drug called Entresto, which is given to people with heart failure, is more effective when taken with or without another drug called Aprepitant.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the primary goal of this medical experiment?
"The primary outcome of this research trial, which will be measured over six hours post-medication administration, is Mean Arterial Blood Pressure (MAP). Secondary objectives encompass Glomerular Filtration Rate (GFR) evaluated through iohexol clearance pre and post LCZ66 on study days; Urine Albumin to Creatinine Ratio (UACR), also determined prior and after the drug's introduction; as well as measuring total urine output from medication intake onwards."
Have any other studies been conducted with regard to LCZ 696?
"Currently, 51 clinical studies are underway to research the effects of LCZ 696. Of these trials, 10 have reached Phase 3 status. Montreal is home base for many of the investigations; however, 1008 sites across the world are also conducting tests on this medication."
Has the Food and Drug Administration indicated its acceptance of LCZ 696 for public use?
"The safety of LCZ 696 is deemed to be a 3 on our team's assessment scale, due to the compound being approved for use in Phase 4 clinical trials."
What is the fullest extent of persons taking part in this research endeavor?
"Affirmative. Clinicaltrials.gov confirms that this study, first posted on May 27th 2021, is actively seeking participants. 80 volunteers need to be recruited from 1 location for the trial to begin."
Are new participants being sought for this clinical experiment?
"The clinical trial is currently searching for volunteers, as per its listing on the clinicaltrials.gov platform which was initially posted in May 2021 and recently adjusted in June 2022."